NCT05302583 Aromatherapy Inhaler Use for HSCT Distress
| NCT ID | NCT05302583 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Cancer Distress |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-06-16 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-06-16 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial will evaluate the feasibility and acceptability of an inhaled aromatherapy stick for patients during the acute inpatient phase after hematopoietic cell transplantation (HCT) . The study will also explore whether aromatherapy use is associated with short-term changes in patient-reported cancer-related distress and coping self-efficacy.
Eligibility Criteria
Inclusion Criteria: * Autologous and Allogeneic patients admitted to E1 for planned HSCT * Patients with hematologic malignancies requiring HSCT * No allergies to lavender or peppermint essential oils * Must have received chemotherapy during preparative regimen (single or multi-agent regimen) * Adult patient over 18 years of age * Able to speak, read, and comprehend English * Willing and capable of providing informed consent Exclusion Criteria: * Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion * Patients receiving a transplant for a germ cell tumor diagnosis * Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical deterioration) * Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4 * History of scleroderma * History of atrial fibrillation * Known history of G6PD deficiency * Allergic to lavender or peppermint essential oils * Pediatric patient 18 years of age or less * Unable to speak, read, and comprehend English * Unwilling or incapable of providing informed consent
Contact & Investigator
Anna Oh, PhD, MPH, RN
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT05302583 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer Distress. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05302583 currently recruiting?
Yes, NCT05302583 is actively recruiting participants. Contact the research team at aoh2@stanford.edu for enrollment information.
Where is the NCT05302583 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT05302583 clinical trial?
NCT05302583 is sponsored by Stanford University. The principal investigator is Anna Oh, PhD, MPH, RN at Stanford University. The trial plans to enroll 50 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.